Tolerance of nasal and oral povidone-iodine antisepsis amid COVID-19 pandemic

Frank et al., Otolaryngology - Head and Neck Surgery, 165:89, Oct 2021
PVP-I for COVID-19
14th treatment shown to reduce risk in February 2021, now with p = 0.000000000016 from 22 studies.
Lower risk for mortality, hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
6,200+ studies for 200+ treatments. c19early.org
Download Meta Analysis
Prospective study of 42 otolaryngology and dental patients, showing low-dose nasal and oral PVP-I solutions to be well-tolerated.
Important missing comments or errors? Let us know.
Frank et al., 3 Oct 2021, preprint, 6 authors.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0